Oramed Pharmaceuticals Inc.
NASDAQ:ORMPBiotechnology
+$0.03 today
- Market cap
- $169.16M
- Beta
- 1.24
- P/E (TTM)
- 1.4
- EPS (TTM)
- $2.70
- Dividend yield
- 6.54%
Volume 0.16M
Average 0.16M
ORMP Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Oramed Pharmaceuticals Inc.NASDAQ: ORMP
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 82.3% from a year ago
Cash & equivalents stood at $13.2M at the end of Q1 FY2026, down 82.3% from a year earlier and down 71.3% from the prior quarter. Over 3 fiscal years it compounded at +4.3% a year.
Context
- Cash & equivalents amounted to 4.9% of total assets at the end of Q1 FY2026, down 45.6 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -82.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 45.95M USD
- Year-over-year change
- -15.6%
- 4-year CAGR
- -12.2%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 45.95M | -15.6% |
| FY2024 | 2024-12-31 | 54.42M | +501.0% |
| FY2023 | 2023-12-31 | 9.06M | -77.6% |
| FY2022 | 2022-12-31 | 40.46M | -47.6% |
| FY2021 | 2021-08-31 | 77.25M | — |
Cash & Equivalents vs competitors
How ORMP compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -82.3% is the lowest of 11, against a peer median of -39.3%.
- Cash & equivalents amounts to 4.9% of total assets for ORMP, versus a peer median of 48.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $94.06M USD | +345.0% | -33.6% | 41.7% | |
| Mar 2026 | $90.42M USD | +48.5% | +4.6% | 88.5% | |
IMAImageneBio Inc | Mar 2026 | $76.05M USD | +106.9% | -16.4% | 55.6% |
| Mar 2026 | $66.52M USD | -54.3% | -19.3% | 30.5% | |
| Mar 2026 | $54.53M USD | -39.0% | +23.0% | 92.6% | |
| Mar 2026 | $50.72M USD | +42.8% | +99.1% | 95.2% | |
| Dec 2025 | $38.35M USD | -51.0% | -21.4% | 68.4% | |
KLRSKalaris Therapeutics Inc | Mar 2026 | $34.43M USD | -65.9% | +217.7% | 31.4% |
| Mar 2026 | €15.01M EUR | -68.3% | -0.5% | 30.7% | |
| Mar 2026 | $13.2M USD | -82.3% | +4.3% | 4.9% | |
| Mar 2026 | $5.94M USD | -39.6% | -34.3% | 27.4% | |
| Peer median (excluding ORMP) | — | -39.3% | -8.5% | 48.7% | |
Competitors are the stored peer set for ORMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Aug 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 77.25M | 40.46M | 9.06M | 54.42M | 45.95M |
| Short-term Investments | 16.9M | 115.26M | 152.99M | 87.51M | 79.95M |
| Net Receivables | 0 | 0 | 0 | 0 | 4.64M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.2M | 1.39M | 537K | 1.29M | 2.74M |
| Total Current Assets | 95.34M | 157.11M | 162.58M | 143.22M | 133.27M |
| Property, Plant & Equipment (Net) | 932K | 1.81M | 1.57M | 1.11M | 1.34M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 6.69M | 2.7M | 56.37M | 10.91M | 93.74M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 25.04M | 24K | 34K | 34K | 2.52M |
| Total Non-current Assets | 32.66M | 4.53M | 57.97M | 12.06M | 97.59M |
| Total Assets | 128M | 161.64M | 220.55M | 155.28M | 230.86M |
| Account Payables | 2.61M | 2.18M | 551K | 789K | 443K |
| Short-term Debt | 130K | 247K | 51.01M | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 3.2M | 0 |
| Deferred Revenue | 2.7M | 1.34M | 0 | 0 | 1.35M |
| Other Current Liabilities | (1.37M) | (191K) | 325K | 1.07M | 2.37M |
| Total Current Liabilities | 6.68M | 5.75M | 53.21M | 5.69M | 19.09M |
| Long-term Debt | 403K | 647K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 11K | 11K | 0 | 0 | 7.91M |
| Deferred Revenue (Non-current) | 4.24M | 4M | 4M | 4M | 3.27M |
| Other Non-current Liabilities | 145K | 82K | 102K | 90K | 314K |
| Total Non-current Liabilities | 4.8M | 4.74M | 4.44M | 4.25M | 12.03M |
| Total Liabilities | 11.48M | 10.49M | 57.66M | 9.93M | 31.12M |
| Common Stock | 424K | 476K | 485K | 480K | 472K |
| Retained Earnings | (114.85M) | (163.08M) | (157.56M) | (176.62M) | (123.44M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 230.2M | 314.42M | 0 | 0 | 0 |
| Minority Interest | 744K | (656K) | (928K) | (918K) | 0 |
| Total Equity | 116.52M | 151.16M | 162.89M | 145.35M | 199.74M |
| Total Debt | 533K | 894K | 51.62M | 372K | 825K |
| Net Debt | (76.71M) | (39.57M) | 42.57M | (54.05M) | (45.12M) |
Oramed Pharmaceuticals Inc.
NASDAQ:ORMP
Intrinsic Alpha fair value
Locked
Current Price
$3.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.